Studies conducted on the use of opioid antagonists, naltrexone and naloxone for the treatment of PCOS, found that this kind of therapy significantly reduced the insulin response to oral glucose tolerance test (OGTT) in a group of hyperinsulinemic patients with PCOS [76]. This evidence concerns the gene INS and polycystic ovary syndrome.